| Ytd | -29.39% | |
| 1y | 27.76% |
| Open | 10.37 | Prev Close | 10.43 | Low | 10.30 | High | 11.05 | Mkt Cap | 19.32M |
| Vol | 51.56K | Avg Vol | 63.52K | EPS | 0.11 | P/E | 98.73 | Forward P/E | 0.52 |
| Beta | 0.94 | Short Ratio | 4.47 | Inst. Own | 7.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 9.69 | 200-d Avg | 15.83 | 1yr Est | 17.00 |
PTN News
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisition
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a bio
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Techs (AMEX:PTN) reported quarterly losses of $(0.37) per share which beat the analyst conse
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerabili
Palatin Technologies (NYSEAMERICAN:PTN) executives highlighted recent financing activity, progress i
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Techs (AMEX:PTN) reported quarterly losses of $(2.86) per share which missed the analyst con
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based ob
Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wal
Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Pa
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensi
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbo
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in p
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milest
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatmen
Boehringer and Palatin Technologies team up to develop potential first-in-class melanocortin recepto
PRINCETON, N.J. , Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today annou
Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Co
Palatin Technologies, Inc. (PTN) Q3 2025 - Earnings Conference Call May 14, 2025 11:00 AM ET Company
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it ind
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarter
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earning
Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company report
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $
During Tuesday's session, 275 companies made new 52-week lows.
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is estimated to report earnings for its f
OnFriday, 143 stocks hit new 52-week lows.
Thursday's session saw 329 companies set new 52-week lows.
On Wednesday, 152 stocks made new 52-week lows.
On Tuesday, 298 companies achieved new lows for the year.
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.